Zoetis Inc. (NYSE:ZTS) Shares Acquired by Valley Brook Capital Group Inc.

Valley Brook Capital Group Inc. lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,168 shares of the company’s stock after purchasing an additional 100 shares during the quarter. Valley Brook Capital Group Inc.’s holdings in Zoetis were worth $428,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ZTS. Blue Bell Private Wealth Management LLC grew its stake in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares during the last quarter. Independence Bank of Kentucky lifted its holdings in Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Ramirez Asset Management Inc. purchased a new position in Zoetis in the 3rd quarter valued at about $35,000. First Financial Corp IN lifted its holdings in Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after purchasing an additional 79 shares in the last quarter. Finally, FinTrust Capital Advisors LLC lifted its holdings in Zoetis by 42.1% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock valued at $45,000 after purchasing an additional 77 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 2,209 shares of company stock valued at $371,293 over the last 90 days. 0.16% of the stock is owned by corporate insiders.

Zoetis Trading Down 0.1 %

ZTS traded down $0.16 on Friday, reaching $167.07. 3,007,125 shares of the company’s stock were exchanged, compared to its average volume of 4,607,073. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company’s 50 day moving average is $168.88 and its 200-day moving average is $178.93. The company has a market cap of $76.41 billion, a price-to-earnings ratio of 32.19, a PEG ratio of 2.61 and a beta of 0.86.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.74%. The company had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter last year, the company earned $1.31 earnings per share. Zoetis’s revenue for the quarter was up 9.5% on a year-over-year basis. Equities analysts predict that Zoetis Inc. will post 5.77 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.03%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Analyst Ratings Changes

A number of research analysts have issued reports on ZTS shares. Barclays reduced their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. The Goldman Sachs Group increased their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Stifel Nicolaus cut their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $216.13.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.